Market Overview

Array Biopharma Announces Binimetinib Continues to Advance in Clinical Development

Related ARRY
15 Biggest Mid-Day Losers For Monday
Array Biopharma Recoups Some Of Its Losses From Sharply Lower Open
The Vetr community has downgraded $ARRY to 4-Stars (Vetr)

Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array BioPharma Inc. (NASDAQ: ARRY) reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib (MEK162), including obligations relating to support for ongoing clinical trials as specified in the agreement.

Array BioPharma

In April 2010, Array entered into an agreement under which Novartis received exclusive worldwide rights to binimetinib.   If Novartis' binimetinib development and commercialization rights are returned to Array, Novartis is required to provide  support for ongoing clinical studies as specified in that agreement.

Posted-In: News FDA Press Releases


Related Articles (ARRY)

View Comments and Join the Discussion!